In vitro radiosensitisation by trabectedin in human cancer cell lines

European Journal of Cancer

Volumn 44, Issue 12, 2008, Pages 1726-1733

  Romero, Jesús ^a   Zapata, Irma ^a   Córdoba, Sofía ^a   Jimeno, José María ^b   López Martín, José Antonio ^b   Tercero, Juan Carlos ^b   La Torre, Alejandro De ^a   Vargas, Juan Antonio ^a   Molerón, Rafael ^a   Sánchez Prieto, Ricardo ^c  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b PHARMAMAR S A   (Spain)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Apoptosis; Flow cytometry; Radiation sensitising agents; Tetrahydroisoquinolines

Indexed keywords

TRABECTEDIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MECHANISM; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIZATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; DIOXOLES; DNA REPAIR; FLOW CYTOMETRY; HELA CELLS; HT29 CELLS; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED;

EID: 48349148066     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.04.013     Document Type: Article

References (45)

1. Rinehart K.L., Holt T.G., and Fregeau N.L. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J Org Chem 55 (1990) 4512-4515
2. Jimeno J.M., Faircloth G., and Cameron L. Progress in the acquisition of new marine-derived anticancer compounds: development of ecteinascidin-743 (ET-743). Drugs Fut 21 (1996) 1155-1165
3. Li W.W., Takahashi N., Jhanwar S., et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 7 (2001) 2908-2911
4. Izbicka E., Lawrence R., Raymond E., et al. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 9 (1998) 981-987
5. Scotlandi K., Perdichizzi S., Manara M.C., et al. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res 8 (2002) 3893-3903
6. Reid J.M., Walker D.L., and Ames M.M. Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. Cancer Chemother Pharmacol 38 (1996) 329-334
7. Valoti G., Nicoletti M.I., Pellegrino A., et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 4 (1998) 1977-1983
8. Hendriks H.R., Fiebig H.H., Giavazzi R., Langdon S.P., Jimeno J.M., and Faircloth G.T. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 10 (1999) 1233-1240
9. Sessa C., de Braud F., Perotti A., et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23 (2005) 1867-1874
10. Delaloge S., Yovine A., Taamma A., et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 19 (2001) 1248-1255
11. Garcia-Carbonero R., Supko J.G., Maki R.G., et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 23 (2005) 5484-5492
12. Le Cesne A., Blay J.Y., Judson I., et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23 (2005) 576-584
13. Yovine A., Riofrio M., Blay J.Y., et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22 (2004) 890-899
14. Zelek L., Yovine A., Brain E., et al. A phase II study of Yondelis® (trabectedin, ET-743) as a 24-hour continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 94 (2006) 1610-1614
15. Pommier Y., Kohlhagen G., Bailly C., Waring M., Mazumder A., and Kohn K.W. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35 (1996) 13303-13309
16. Moore B.M., Seaman F.C., Wheelhouse R.T., and Hurley L.H. Mechanism for the catalytic activation of ecteinascidin 743 and its subsequent alkylation of guanine N2. Journal of The American Chemical Society 120 (1998) 2490-2491
17. Jin S., Gorfajn B., Faircloth G., and Scotto K.W. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A 97 (2000) 6775-6779
18. Minuzzo M., Marchini S., Broggini M., Faircloth G., D'Incalci M., and Mantovani R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 97 (2000) 6780-6784
19. Bonfanti M., La Valle E., Fernandez Sousa Faro J.M., et al. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des 14 (1999) 179-186
20. Friedman D., Hu Z., Kolb E.A., Gorfajn B., and Scotto K.W. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 62 (2002) 3377-3381
21. Takebayashi Y., Goldwasser F., Urasaki Y., Kohlhagen G., and Pommier Y. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res 7 (2001) 185-191
22. Erba E., Bergamaschi D., Bassano L., et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37 (2001) 97-105
23. Soares D.G., Escarguel A.E., Poindessous V., et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A 104 (2007) 13062-13067
24. Damia G., Silvestri S., Carrassa L., et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 92 (2001) 583-588
25. Takebayashi Y., Pourquier P., Zimonjic D.B., et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7 (2001) 961-966
26. Takahashi N., Li W., Banerjee D., et al. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res 62 (2002) 6909-6915
27. Martinez N., Sanchez-Beato M., Carnero A., et al. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther 4 (2005) 814-823
28. Simoens C., Korst A.E., De Pooter C.M., et al. In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects. Br J Cancer 89 (2003) 2305-2311
29. Gillies R.J., Didier N., and Denton M. Determination of cell number in monolayer cultures. Anal Biochem 159 (1986) 109-113
30. Carlton J.C., Terry N.H., and White R.A. Measuring potential doubling times of murine tumors using flow cytometry. Cytometry 12 (1991) 645-650
31. Erba E., Bergamaschi D., Bassano L., et al. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743). Br J Cancer 82 (2000) 1732-1739
32. Ghielmini M., Colli E., Erba E., et al. In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743). Ann Oncol 9 (1998) 989-993
33. Puchalski T.A., Ryan D.P., Garcia-Carbonero R., et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 50 (2002) 309-319
34. van Kesteren C., Cvitkovic E., Taamma A., et al. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 6 (2000) 4725-4732
35. Taamma A., Misset J.L., Riofrio M., et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 19 (2001) 1256-1265
36. van Kesteren C., Twelves C., Bowman A., et al. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs 13 (2002) 381-393
37. Twelves C., Hoekman K., Bowman A., et al. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 39 (2003) 1842-1851
38. Lau L., Supko J.G., Blaney S., et al. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clin Cancer Res 11 (2005) 672-677
39. Villalona-Calero M.A., Eckhardt S.G., Weiss G., et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res 8 (2002) 75-85
40. Lee C.M., Fuhrman C.B., Planelles V., et al. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res 12 (2006) 250-256
41. Gajate C., An F., and Mollinedo F. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J Biol Chem 277 (2002) 41580-41589
42. Tavecchio M., Natoli C., Ubezio P., Erba E., and D'Incalci M. Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach. Cell Prolif 40 (2007) 885-904
43. Moneo V., Leal J., Blanco C., et al. Extreme sensitivity to Yondelis (trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem 100 (2007) 339-348
44. Damia G., and D'Incalci M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 43 (2007) 1791-1801
45. Tavecchio M., Simone M., Erba E., et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 44 (2008) 609-618